These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25188229)

  • 21. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
    Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
    J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of National Colorectal Cancer Screening Program in Croatia (2007-2011).
    Katičić M; Antoljak N; Kujundžić M; Stamenić V; Skoko Poljak D; Kramarić D; Stimac D; Strnad Pešikan M; Samija M; Ebling Z
    World J Gastroenterol; 2012 Aug; 18(32):4300-7. PubMed ID: 22969192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.
    Iannone A; Losurdo G; Pricci M; Girardi B; Massaro A; Principi M; Barone M; Ierardi E; Di Leo A
    J Gastrointest Cancer; 2016 Jun; 47(2):143-51. PubMed ID: 26922358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic Value of Fecal MicroRNAs for Colorectal Cancer: a Meta-Analysis.
    Wang C; Zhao K; Rong Q
    Clin Lab; 2015; 61(12):1845-53. PubMed ID: 26882806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stages of Adoption for Fecal Occult Blood Test and Colonoscopy Tests for Colorectal Cancer Screening in Korea.
    Bui NC; Cho HN; Lee YY; Suh M; Park B; Jun JK; Kim Y; Choi KS
    Cancer Res Treat; 2018 Apr; 50(2):416-427. PubMed ID: 28494531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninvasive testing for colorectal cancer: a review.
    Ouyang DL; Chen JJ; Getzenberg RH; Schoen RE
    Am J Gastroenterol; 2005 Jun; 100(6):1393-403. PubMed ID: 15929776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fecal immunochemical test accuracy in average-risk colorectal cancer screening.
    Hernandez V; Cubiella J; Gonzalez-Mao MC; Iglesias F; Rivera C; Iglesias MB; Cid L; Castro I; de Castro L; Vega P; Hermo JA; Macenlle R; Martínez-Turnes A; Martínez-Ares D; Estevez P; Cid E; Vidal MC; López-Martínez A; Hijona E; Herreros-Villanueva M; Bujanda L; Rodriguez-Prada JI;
    World J Gastroenterol; 2014 Jan; 20(4):1038-47. PubMed ID: 24574776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of faecal occult blood positivity on detection rates and positive predictive value of CT colonography when screening for colorectal neoplasia.
    Plumb AA; Taylor SA; Halligan S
    Clin Radiol; 2015 Oct; 70(10):1104-9. PubMed ID: 26145187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
    Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
    Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.
    Kalimutho M; Del Vecchio Blanco G; Cretella M; Mannisi E; Sileri P; Formosa A; Pallone F; Federici G; Bernardini S
    Int J Colorectal Dis; 2011 May; 26(5):583-92. PubMed ID: 21225430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Fecal Occult Blood Testing as a Diagnostic Tool for Clinical Indications: A Systematic Review and Meta-Analysis.
    Lee MW; Pourmorady JS; Laine L
    Am J Gastroenterol; 2020 May; 115(5):662-670. PubMed ID: 31972617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multitarget stool DNA test compared with fecal occult blood test for colorectal cancer screening.
    Yang C; Wu W; Yang Y; Yang X; Sun J; Zhang W; Liu K; Ying H; Jiang S; Yu X; Shi Y; Zhou Y; Zhu S; Xu Y; Ding Y; Xie L; Cai B; Xin X; Chen P; Zhao R; Wu Y
    Oncol Lett; 2020 Aug; 20(2):1193-1200. PubMed ID: 32724359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Screening for colorectal cancer using immunological fecal occult blood test in inpatients].
    Kawabata H; Inoue N; Kawakatsu Y; Okazaki Y; Hitomi M; Miyata M; Motoi S
    Nihon Shokakibyo Gakkai Zasshi; 2018; 115(4):377-384. PubMed ID: 29643290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Value of Methylated
    Xie L; Jiang X; Li Q; Sun Z; Quan W; Duan Y; Li D; Chen T
    Front Oncol; 2018; 8():247. PubMed ID: 30013949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fecal occult blood test as a tool for improved outpatient qualification for colonoscopy. A single-center experience and 10-year follow-up survey.
    Banaszkiewicz Z; Budzyński J; Tojek K; Jarmocik P; Frasz J; Mrozowski M; Świtoński M; Jawień A
    Adv Med Sci; 2017 Mar; 62(1):171-176. PubMed ID: 28282604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.
    Green BB; Anderson ML; Chubak J; Fuller S; Meenan RT; Vernon SW
    Cancer; 2016 Jan; 122(2):312-21. PubMed ID: 26488332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical value of combining serum tumor marker detection with fecal occult blood testing in diagnosing colorectal cancer.
    Zhou H; Wang XC; Yuan BB; Lu BB
    J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36515627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of the OC Sensor
    Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
    Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study.
    Levi Z; Birkenfeld S; Vilkin A; Bar-Chana M; Lifshitz I; Chared M; Maoz E; Niv Y
    Int J Cancer; 2011 May; 128(10):2415-24. PubMed ID: 20658527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.